BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20177704)

  • 1. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
    Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
    Krasteva ME; Bozhanov SS; Antov GG; Gospodinova ZI; Angelov SG
    Neoplasma; 2012; 59(1):85-91. PubMed ID: 22103901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
    Ding SL; Sheu LF; Yu JC; Yang TL; Chen BF; Leu FJ; Shen CY
    Br J Cancer; 2004 May; 90(10):1995-2001. PubMed ID: 15138484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
    Rio PG; Pernin D; Bay JO; Albuisson E; Kwiatkowski F; De Latour M; Bernard-Gallon DJ; Bignon YJ
    Int J Oncol; 1998 Oct; 13(4):849-53. PubMed ID: 9735416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Hallajian Z; Mahjoubi F; Nafissi N
    Breast Cancer; 2017 Jul; 24(4):624-634. PubMed ID: 28058614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
    Azizi Tabesh G; Izadi P; Fereidooni F; Emami Razavi AN; Tavakkoly Bazzaz J
    Cancer Invest; 2017 Jan; 35(1):36-42. PubMed ID: 27901576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
    Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
    Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
    Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
    Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
    Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
    Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
    Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
    J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
    Rhiem K; Todt U; Wappenschmidt B; Klein A; Wardelmann E; Schmutzler RK
    Anticancer Res; 2010 Sep; 30(9):3445-9. PubMed ID: 20944121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
    Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
    Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Guarneri V; Dieci MV; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Nanni O; Piacentini F; Orvieto E; Griguolo G; Curtarello M; Urso L; Paré L; Chic N; D'Amico R; Prat A; Conte P
    Clin Cancer Res; 2020 Nov; 26(22):5843-5851. PubMed ID: 32843527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.